MDMA induces EPSP-spike potentiation in rat ventral hippocampus in vitro via serotonin and noradrenaline release and coactivation of 5-HT4 and β1 receptors

Neuropsychopharmacology

Volumn 33, Issue 6, 2008, Pages 1464-1475

  Mlinar, Boris ^a   Mascalchi, Simona ^a   Morini, Raffaella ^a   Giachi, Filippo ^a   Corradetti, Renato ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Evoked potentials; Hippocampus; MDMA; Noradrenaline; Rat; Serotonin

Indexed keywords

3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; 3 INDOLECARBOXYLIC ACID 2 (1 PIPERIDINYL)ETHYL ESTER; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; BETA 1 ADRENERGIC RECEPTOR; CITALOPRAM; FENCLONINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NISOXETINE; NORADRENALIN; SB 258585; SEROTONIN 4 RECEPTOR; SEROTONIN 6 ANTAGONIST; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; EVOKED RESPONSE; EXCITATORY POSTSYNAPTIC POTENTIAL; GABAERGIC TRANSMISSION; MALE; NONHUMAN; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; SEROTONIN RELEASE; SPIKE WAVE;

ADRENERGIC AGENTS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; EXCITATORY POSTSYNAPTIC POTENTIALS; HIPPOCAMPUS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NOREPINEPHRINE; PATCH-CLAMP TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN; SEROTONIN AGENTS; STATISTICS, NONPARAMETRIC;

EID: 42049123019     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301512     Document Type: Article

References (75)

1. Anderson WW, Collingridge GL (2001). The LTP program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events. J Neurosci Methods 108: 71-83.
2. Andrade R (1998). Regulation of membrane excitability in the central nervous system by serotonin receptor subtypes. Ann NY Acad Sci 861: 190-203.
3. Bannerman DM, Rawlins JNP, McHugh SB, Deacon RMJ, Yee BK, Bast T et al (2004). Regional dissociations within the hippocampus-memory and anxiety. Neurosci Biobehav Rev 28: 273-283.
4. Bardgett ME, Henry JD (1999). Locomotor activity and accumbens Fos expression driven by ventral hippocampal stimulation require D1 and D2 receptors. Neuroscience 94: 59-70.
5. Battaglia G, Yeh SY, O'Hearn E, Molliver ME, Kuhar MJ, De Souza EB (1987). 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 242: 911-916.
6. Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1988). Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149: 159-163.
7. Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, Heils A et al (1998). Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ('Ecstasy') in serotonin transporter-deficient mice. Mol Pharmacol 53: 649-655.
8. Brevard ME, Meyer JS, Harder JA, Ferris CF (2006). Imaging brain activity in conscious monkeys following oral MDMA ('ecstasy'). Magn Reson Imaging 24: 707-714.
9. Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI et al (2001). Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60: 1181-1188.
10. Check E (2004). Psychedelic drugs: the ups and downs of ecstasy. Nature 429: 126-128.
11. Colino A, Halliwell JV (1987). Differential modulation of three separate K-conductances in hippocampal CA1 neurons by serotonin. Nature 328: 73-77.
12. Corradetti R, Ballerini L, Pugliese AM, Pepeu G (1992). Serotonin blocks the long-term potentiation induced by primed burst stimulation in the CA1 region of rat hippocampal slices. Neuroscience 46: 511-518.
13. de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN et al (2000). Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 49: 104-109.
14. Doblin R (2002). A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA. J Psychoactive Drugs 34: 185-194.
15. Dolcos F, LaBar KS, Cabeza R (2004). Interaction between the amygdala and the medial temporal lobe memory system predicts better memory for emotional events. Neuron 42: 855-863.
16. Downing J (1986). The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 18: 335-340.
17. Dumont GJH, Verkes RJ (2006). A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol 20: 176-187.
18. Fitzgerald JL, Reid JJ (1990). Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. Eur J Pharmacol 191: 217-220.
19. Fitzgerald JL, Reid JJ (1993). Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices. Naunyn Schmiedebergs Arch Pharmacol 347: 313-323.
20. Gelinas JN, Nguyen PV (2005). β-Adrenergic receptor activation facilitates induction of a protein synthesis-dependent late phase of long-term potentiation. J Neurosci 25: 3294-3303.
21. Garrett AS, Maddock RJ (2006). Separating subjective emotion from the perception of emotion-inducing stimuli: an fMRI study. Neuroimage 33: 263-274.
22. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Pharmacol Rev 55: 463-508.
23. Grinspoon L, Bakalar JB (1986). Can drugs be used to enhance the psychotherapeutic process? Am J Psychother 40: 393-404.
24. Hagan JJ, Price GW, Jeffrey P, Deeks NJ, Stean T, Piper D et al (2000). Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist. Br J Pharmacol 130: 539-548.
25. Heginbotham LR, Dunwiddie TV (1991). Long-term increases in the evoked population spike in the CA1 region of rat hippocampus induced by beta-adrenergic receptor activation. J Neurosci 11: 2519-2526.
26. Herman JP, Mueller NK (2006). Role of the ventral subiculum in stress integration. Behav Brain Res 174: 215-224.
27. Hirst WD, Minton JA, Bromidge SM, Moss SF, Latter AJ, Riley G et al (2000). Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue. Br J Pharmacol 130: 1597-1605.
28. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN (2004). Comparative pharmacology of human beta-adrenergic receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 369: 151-159.
29. Hoffman DA, Johnston D (1999). Neuromodulation of dendritic action potentials. J Neurophysiol 81: 408-411.
30. Hyttel J, Larsen JJ (1985). Neurochemical profile of Lu 19-005, a potent inhibitor of uptake of dopamine, noradrenaline, and serotonin. J Neurochem 44: 1615-1622.
31. Irvine RJ, Keane M, Felgate P, McCann UD, Callaghan PD, White JM (2006). Plasma drug concentrations and physiological measures in 'dance party' participants. Neuropsychopharmacology 31: 424-430.
32. Johnson MP, Hoffman AJ, Nichols DE (1986). Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132: 269-276.
33. Katsuki H, Izumi Y, Zorumski CF (1997). Noradrenergic regulation of synaptic plasticity in the hippocampal CA1 region. J Neurophysiol 77: 3013-3020.
34. Kelley AE, Domesick VB (1982). The distribution of the projection from the hippocampal formation to the nucleus accumbens in the rat: an anterograde- and retrograde-horseradish peroxidase study. Neuroscience 7: 2321-2335.
35. Leonardi ET, Azmitia EC (1994). MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 10: 231-238.
36. Liechti ME, Baumann C, Gamma A, Vollenweider FX (2000). Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22: 513-521.
37. Madison DV, Nicoll RA (1986). Actions of noradrenaline recorded intracellularly in rat hippocampal CA1 pyramidal neurones, in vitro. J Physiol 372: 221-244.
38. 1B receptors located on CA1 pyramidal neurons. Eur J Neurosci 18: 1559-1571.
39. Mlinar B, Mascalchi S, Mannaioni G, Morini R, Corradetti R (2006). 5-HT4 receptor activation induces long-lasting EPSP-spike potentiation in CA1 pyramidal neurons. Eur J Neurosci 24: 719-731.
40. Mlinar B, Pugliese AM, Corradetti R (2001). Selective inhibition of local excitatory synaptic transmission by serotonin through an unconventional receptor in the CA1 region of rat hippocampus. J Physiol 534: 141-158.
41. Mlinar B, Tatini F, Ballini C, Nencioni S, Della Corte L, Corradetti R (2005). Differential autoinhibition of 5-HT neurones by 5-HT in dorsal raphe nucleus. NeuroReport 16: 1351-1355.
42. Mongeau R, Blier P, De Montigny C (1997). The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Brain Res Rev 23: 145-195.
43. Morton J (2005). Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol 5: 79-86.
44. Mueller AL, Hoffer BJ, Dunwiddie TV (1981). Noradrenergic responses in rat hippocampus: evidence for medication by alpha and beta receptors in the in vitro slice. Brain Res 214: 113-126.
45. Nichols DE (1986). Differences between the mechanisms of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18: 305-313.
46. Nichols DE, Hoffman AJ, Oberlender RA, Jacob III P, Shulgin AT (1986). Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. J Med Chem 29: 2009-2015.
47. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME (1988). Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 8: 2788-2803.
48. Ohtsuki T, Ishiguro H, Detera-Wadleigh SD, Toyota T, Shimizu H, Yamada K et al (2002). Association between serotonin 4 receptor gene polymorphisms and bipolar disorder in Japanese case-control samples and the NIMH Genetics Initiative Bipolar Pedigrees. Mol Psychiatry 7: 954-961.
49. Oleskevich S, Descarries L (1990). Quantified distribution of the serotonin innervation in adult rat hippocampus. Neuroscience 34: 19-33.
50. Oleskevich S, Descarries L, Lacaille JC (1989). Quantified distribution of the noradrenaline innervation in the hippocampus of adult rat. J Neurosci 9: 3803-3815.
51. Otmakhova NA, Lewey J, Asrican B, Lisman JE (2005). Inhibition of perforant path input to the CA1 region by serotonin and noradrenaline. J Neurophysiol 94: 1413-1422.
52. Parrott AC (2001). Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 16: 557-577.
53. Peleg-Raibstein D, Feldon J (2006). Effects of dorsal and ventral hippocampal NMDA stimulation on nucleus accumbens core and shell dopamine release. Neuropharmacology 51: 947-957.
54. Peleg-Raibstein D, Pezze MA, Ferger B, Zhang WN, Murphy CA, Feldon J et al (2005). Activation of dopaminergic neurotransmission in the medial prefrontal cortex by N-methyl-D-aspartate stimulation of the ventral hippocampus in rats. Neuroscience 132: 219-232.
55. Peroutka SJ, Newman H, Harris H (1988). Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1: 273-277.
56. Premkumar LS, Ahern GP (1995). Blockade of a resting potassium channel and modulation of synaptic transmission by ecstasy in the hippocampus. J Pharmacol Exp Ther 274: 718-722.
57. Pugliese AM, Passani MB, Corradetti R (1998). Effect of the selective 5-HT1A receptor antagonist WAY 100635 on the inhibition of e.p.s.ps produced by 5-HT in the CA1 region of rat hippocampal slices. Br J Pharmacol 124: 93-100.
58. Richardson MP, Strange BA, Dolan RJ (2004). Encoding of emotional memories depends on amygdala and hippocampus and their interactions. Nat Neurosci 7: 278-285.
59. Robbins TW, Everitt BJ (1996). Neurobehavioural mechanisms of reward and motivation. Curr Opin Neurobiol 6: 228-236.
60. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI et al (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39: 32-41.
61. Rudnick G, Wall SC (1992). The molecular mechanism of 'ecstasy' [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA 89: 1817-1821.
62. Sanchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A et al (2003). Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 167: 353-362.
63. Schaefer HS, Putnam KM, Benca RM, Davidson RJ (2006). Event-related functional magnetic resonance imaging measures of neural activity to positive social stimuli in pre- and post-treatment depression. Biol Psychiatry 60: 974-986.
64. Schroeter S, Apparsundaram S, Wiley RG, Miner LH, Sesack SR, Blakely RD (2000). Immunolocalization of the cocaine- and antidepressant-sensitive l-norepinephrine transporter. J Comp Neurol 420: 211-232.
65. Schuldiner S, Steiner-Mordoch S, Yelin R, Wall SC, Rudnick G (1993). Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol Pharmacol 44: 1227-1231.
66. Scorza MC, Carrau C, Silveira R, Zapata-Torres G, Cassels BK, Reyes-Parada M (1997). Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives: structure-activity relationships. Biochem Pharmacol 54: 1361-1369.
67. Segal M (1990). Serotonin attenuates a slow inhibitory postsynaptic potential in rat hippocampal neurons. Neuroscience 36: 631-641.
68. Steele TD, Nichols DE, Yim GK (1987). Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol 36: 2297-2303.
69. Stein DJ, Rink J (1999). Effects of 'Ecstasy' blocked by serotonin reuptake inhibitors. J Clin Psychiatry 60: 485.
70. Strange BA, Dolan RJ (2004). Beta-adrenergic modulation of emotional memory-evoked human amygdala and hippocampal responses. Proc Natl Acad Sci USA 101: 11454-11458.
71. Thomas MJ, Moody TD, Makhinson M, O'Dell TJ (1996). Activity-dependent beta-adrenergic modulation of low frequency stimulation induced LTP in the hippocampal CA1 region. Neuron 17: 475-482.
72. van Groen T, Wyss JM (1990). Extrinsic projections from area CA1 of the rat hippocampus: olfactory, cortical, subcortical, and bilateral hippocampal formation projections. J Comp Neurol 302: 515-528.
73. Verrico CD, Miller GM, Madras BK (2007). MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl) 189: 489-503.
74. Verwer RW, Meijer RJ, Van Uum HF, Witter MP (1997). Collateral projections from the rat hippocampal formation to the lateral and medial prefrontal cortex. Hippocampus 7: 397-402.
75. Villani F, Johnston D (1993). Serotonin inhibits induction of long-term potentiation at commissural synapses in hippocampus. Brain Res 606: 304-308.